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Background: Streptococcus sanguinis (S.sanguinis), a predominant bacterium in the human oral cavity, has been
widely associated with the development of infective endocarditis. Platelets play both a haemostatic function and
can influence both innate and adaptive immune responses. Previous studies have shown that S.sanguinis can
interact with, and activate, platelets.
Results: The aim of this study was to determine whether S.sanguinis stimulates the release of matrix
metalloproteinases (MMPs) 1, 2 and 9 and the pro-inflammatory mediators SDF-1, VEGF and sCD40L, from platelets
and to subsequently pharmacologically address the release mechanism (s). S.sanguinis stimulated the release of
MMP-1, SDF-1, VEGF and sCD40L from platelets and inhibitors of cyclooxygenase and phosphatidylinositol 3-kinase,
and antagonists of the αIIbβ3 integrin and glycoprotein Ib, each inhibited the secretion of all factors.
Conclusions: Therefore the release of MMP-1, SDF-1, VEGF and sCD40L occurs late in the platelet response to
S.sanguinis and highlights the complex intracellular signalling pathways stimulated in response to S.sanguinis which
lead to haemostasis, MMP and pro-inflammatory mediator secretion.
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The oral cavity is one of the most common gateways of
entry of bacteria, including Streptococcus sanguinis (S. san-
guinis) an organism which has been implicated in the de-
velopment of infective endocarditis [1], into the blood [2].
A correlation exists between periodontitis, where there is
an increased incidence of bacteremias [3], and the devel-
opment of cardiovascular disease [4], although the causal-
ity is controversial [5]. Multiple studies have demonstrated
that S. sanguinis can activate human platelets in a strain
and donor dependent manner [6], and therefore it is pos-
sible that platelets play a central role in any relationship
between periodontitis and cardiovascular pathologies [6].
Traditionally platelets have been considered solely as
components of haemostatis and by extension the patho-
logical process of thrombosis [7,8]. However, it is now
clear that platelets are innate immune cells and are* Correspondence: fabrice.cognasse@univ-st-etienne.fr
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unless otherwise stated.associated with the early stages of atherosclerosis and
other inflammatory conditions [9-11]. Platelets contain in,
and secrete from, alpha granules a range of soluble immu-
nomodulatory factors such as Stromal cell–derived factor
(SDF)-1/CXCL12, a member of the CXC chemokine fam-
ily and Vascular Endothelial Growth Factor (VEGF), a
sub-family of growth factors, stimulate vasculogenesis and
angiogenesis [12]. Furthermore, CD40 ligand (CD40L,
CD154), of which approximately 95% of its soluble form
(sCD40L) is generated from platelets, is a modulator of
humoral and cellular immunity, has pro-inflammatory
properties and provides a link between the immune sys-
tem and atherothrombosis [13].
Several recent data, including our own, demonstrate that
platelets have the capacity to sense external signals through
a single type of pathogen recognition receptor and differen-
tially adjust the innate immune response by the appropriate
secretion of a number of cytokines/chemokines and some
of their receptors [14,15]. Italiano and colleagues initially
demonstrated that there are two discrete sub-populations
of platelet alpha granules, one containing pro-angiogenic
factors and one containing anti-angiogenic factors [16,17];ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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eity among these granules [18]. This has led to the concept
of differential alpha granule release, although the mecha-
nisms remain unknown [17].
Matrix MetalloProteinases (MMPs) constitute a family of
zinc- and calcium-dependent proteinases that are involved
in the turnover of the extracellular matrix (ECM) of con-
nective tissue. They degrade most components of the ECM
and participate in a variety of pathological processes, in-
cluding atherosclerosis, myocardial infarction and aortic an-
eurysms, as well as tumour growth and metastasis [19].
MMP-1 is expressed on the surface of resting platelets and,
following platelet activation, its levels are upregulated and
its activity engaged [20]. There is less MMP-2 than MMP-1
on the platelet surface, and the presence of both MMP-3
and MMP-9 is controversial [20]. In addition to its effects
on the extracellular matrix, MMP-1 can regulate outside-
in signalling in platelets resulting in the phosphotyro-
sine phosphorylation, and subsequent redistribution, of
β3 integrins as a pre-requisite for platelet aggregation [20].
Interestingly, collagen can activate MMP-1, which in
turn cleaves the platelet protease activating receptor, PAR-
1, with the resultant engagement of the receptor and
enhanced platelet activation [21]. To date there are no re-
ports of the effects of S. sanguinis on MMPs in platelets.Figure 1 Streptococcus sanguinis-induced soluble molecule secretion
2017–78 (n = 15), collagen (2 μg/ml; n = 5) or saline control (Unstimulated;
sCD40L, (B) VEGF, (C) SDF-1, (D) MMP-1, (E) MMP-2 and (F) MMP-9 in the r
of several individual experiments using the platelets from different donors
with respect to saline control; *P < 0.05 with respect to the saline control).The aim of this study was to determine whether S. san-
guinis releases platelet MMPs (MMP-1, 2 and 9) and to
pharmacologically address the mechanism by which the
MMPs and pro-inflammatory mediators (SDF-1, VEGF
and sCD40L) are released.Results and discussion
Kerrigan and colleagues have suggested that the interaction
between S sanguinis and GPIb on platelets is not only im-
portant for the pathogenesis of infective endocarditis but
may also play a contributory role in some cases of myocar-
dial infarction [22]. Studies have shown that plasma levels
of sCD40L is a predictor of recurrent cardiovascular disor-
ders (e.g. myocardial infarction and stroke) [23]. As previ-
ously observed [24], S. sanguinis 2017–78 stimulated the
release of significant amounts of sCD40L from platelets
(Figure 1A), consistent with Kerrigan and colleagues pro-
posed role for platelets in S sanguinis-induced myocardial
infarction [22]. The secretion of sCD40L was accompanied
by the secretion of VEGF (Figure 1B), SDF-1 (Figure 1C)
and MMP-1 (Figure 1D). In each case, the level of secre-
tion elicited by S. sanguinis 2017–78 was statistically simi-
lar to that elicited by the soluble positive control collagen
(Figure 1A–D).from platelets. Platelets were stirred in with either S. sanguinis strain
n = 11). Release reactions were terminated and the levels of (A)
eleasates determined by multi-plex luminex. Results are mean ± SEM
and subsequently analyzed using the Mann–Whitney U-test (#P < 0.05
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lease of MMP-2 (Figure 1E) or MMP-9 (Figure 1F). This
constitutes the first demonstration that the oral micro-
organism S. sanguinis can induce the secretion of a tissue-
destructive molecule (MMP-1) from platelets to the local
vasculature, thus potentially participating in the break-
down of the ECM at sites of vascular lesion. The func-
tional significance of the secretion of MMP-1 is unclear. A
novel autocrine role for MMP-1 in collagen-stimulated
platelets has been proposed, whereby collagen converts in-
active MMP-1 to active MMP-1 which in turn cleaves the
thrombin receptor PAR-1 exposing the ligand and leading
to full platelet activation [20]. A similar mechanism in
S. sanguinis-induced platelet activation is attractive as S.
sanguinis and collagen utilise many similar intracellular
signalling pathways [25]. To date the effects of PAR-1 re-
ceptor antagonists, such as SCH 530398, on platelet acti-
vation induced by either collagen or S. sanguinis have not
been examined. Interestingly, however, certain strains of
Porphyromonas gingivalis have been shown to activate
platelets via the PAR-1 and PAR-4 thrombin receptors on




Figure 2 Effects of inhibitors on Streptococcus sanguinis induced sCD
platelets. Platelets were pre-incubated with either aspirin (100 μM; 20 min
n = 5), AN51 (0.165 mg/mL, 5 mins; n = 5) or the saline control then stirred
and the levels of sCD40L in the releasates determined by multi-plex lumine
representing median, upper and lower quartiles of several individual exper
analyzed using the Mann–Whitney U-test (*P < 0.05 with respect to saline ceffect on this activation, and therefore it is clear that a
complex mechanism is involved [27] and a role for MMP-
1 cannot be discounted.
The absence of MMP-2 secretion may reflect the subcel-
lular localisation of MMP-2 within the platelet. Studies by
Sawicki and colleagues suggest that MMP-2 is localised to
the cytosol rather than to granules [28]. Although in the
same studies MMP-2 was secreted in activated platelets
[28], it is possible that the weak nature of platelet activa-
tion by S. sanguinis cannot stimulate this release.
The presence, secretion and release of MMP-9 from
platelets is controversial. Some studies suggest that plate-
lets do not secrete MMP-9 [29,30], whereas others report,
not only that MMP-9 is secreted from platelets in vivo,
but that it plays a crucial role in sCD40L release in patho-
logical conditions such as Behçet’s disease [31] and ab-
dominal sepsis [32].
To determine the potential roles played by individual sig-
nalling pathways in the secretion of sCD40L, VEGF, SDF-1
and MMP-1 in response to S.sanguinis, we employed various
inhibitors of biochemical pathways at concentrations previ-




40L (A), VEGF (B), SDF-1 (C) and MMP-1 (D) secretion from
s.; n = 7), wortmannin (100 nM; 2 mins; n = 5), RGDS (1 mM; 5 mins;
with S. sanguinis strain 2017–78. Release reactions were terminated
x. Results are shown as box plots with whiskers for the data range
iments using the platelets from different donors and subsequently
ontrol; #P < 0.05 with respect to S. sanguinis strain 2017–78).
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pathways, although recognising the potential for non-
selective actions.
We have previously shown roles for GPIb, COX, the
αIIbβ3 integrin and PI3K in S. sanguinis-induced platelet
aggregation [25,33,34]. Consistent with the aggregation
results [24], pre-treatment of platelets with the GPIb an-
tagonist AN51 (0.165 mg/mL, 5mins.), the COX inhibi-
tor aspirin (100 μM; 20 min), the αIIbβ3 integrin
antagonist RGDS (1 mM; 5 mins.) or the PI3K inhibitor
wortmannin (100 nM; 2 mins.) each significantly de-
creased S. sanguinis strain 2017-78-induced secretion of
sCD40L (Figure 2A).
Pretreatment of platelets with the same inhibitors also
decreased the secretion of VEGF (Figure 2B), SDF-1
(Figure 2C) and MMP-1 (Figure 2D) consistent with roles
for GPIb, COX, the αIIbβ3 integrin and PI3K in the secre-
tion of these proteins. The precise sublocalisation of SDF-1,
VEGF and MMP-1 within the individual heterogenic popu-
lation of granules is unknown. However, the current obser-
vations suggest, either that SDF-1, VEGF and MMP-1 are
contained in the same granule population, or that the gran-
ule populations containing the proteins are regulated by the
same signalling pathways.
Conclusions
The concept of differing signalling pathways regulating the
release of the individual populations of alpha granules was
introduced by Italiano and Batinelli [17]. The pathway(s) in-
volved in secretion has not been established. However as
secretion was sensitive to inhibition by RGDS, it appears
that it occurs distal to the engagement of the αIIbβ3 integ-
rin. Speculatively this could lead to the incorporation, and
activation, of ERK into the cytoskeleton [35], Rac activity,
cytoskeletal rearrangement [36] and the subsequent alpha
granule secretion [37]. Further description of their mecha-
nisms of action will expand our understanding of platelet
activation and oral/mucosal inflammatory process and pro-
duce new therapeutic strategies.Methods
Materials
S. sanguinis strain 2017–78 was a gift from Dr M. Herzberg
(University of Minnesota) [38]. Blood Agar Base No. 2 was
obtained from Oxoid Inc. (Nepean, ON, Canada) and
sheep’s blood from Atlas Laboratories (Winnipeg, MB,
Canada). Collagen, the cyclo-oxygenase (COX) inhibitor
aspirin, the phosphatidylinositol 3-kinase (PI3K) inhibi-
tor wortmannin, the peptise αIIbβ3 integrin antagonist
Argine-Glycine-Aspartic Acid-Serine (RGDS), and the
GP (glycoprotein) Ib receptor blocker AN51 were all
purchased from Sigma-Aldrich Canada Ltd (Oakville,
ON, Canada).Blood collection
The study was approved by the Research Ethics Board of
the University of Manitoba. Blood was collected after in-
formed consent, from healthy human volunteers who had
denied taking medication known to interfere with platelet
function. Platelet-rich plasma (PRP) was prepared by cen-
trifugation (200 × g; 20 min). S. sanguinis strain 2017–78
was prepared as previously reported [24]. PRP was stirred
with S. sanguinis strain 2017–78 in the presence of the in-
hibitor or vehicle control, and was aggregation monitored
continuously. At a time corresponding to that which
S. sanguinis strain 2017–78 induced maximal aggregation,
the release was terminated, the sample was centrifuged
and the supernatants stored at -80 ºC until assayed [24].
Soluble factor detection
The levels of soluble factors MMPs (MMP-1, 2 and 9) and
pro-inflammatory mediators (SDF-1, VEGF and sCD40L)
were measured in duplicate from the releasates by multi-
plex luminex kits (Bio-Rad, Marnes-la-Coquette, France).
Absorbance at 450 nm was determined using an ELISA
reader (Miltiskan EX, Labsystem, Helsinki, Finland), as pre-
viously reported [39].
Statistical analysis
Inter-experiment comparisons of S. sanguinis strain 2017-
78-induced MMPs and cytokines release were analyzed by
means of the paired t-test. The effects of inhibitors on S.
sanguinis strain 2017-78-induced secretion were analyzed
using the non-parametric Mann–Whitney U-test. Results
are shown as box plots with whiskers for the data range
representing median, upper and lower quartiles and a P-
value < 0.05 was considered to be significant.
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